T cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous disease in which genetic lesions coordinately affect cell proliferation, differentiation, and survival of thymocytes ([@bib14]; [@bib25]). T-ALL accounts for 15% of pediatric and 25% of adult ALL cases. Importantly, significant differences in outcome are present between pediatric and adult T-ALL ([@bib27]). Thus, although \>70% of children achieve long lasting complete remissions, only 50% of adult T-ALL patients are currently cured. In addition, pediatric and adult T-ALLs show marked differences in the frequency of specific genetic lesions. For example, chromosomal translocation and aberrant expression of the *TAL1* and *TLX3* oncogenes are highly prevalent in children, but rare in adults. In contrast, translocations activating *TLX1* are rarely found in pediatric leukemias but represent one third of adult T-ALL cases ([@bib15], [@bib16]).

RESULTS AND DISCUSSION
======================

To gain more insight in the genetic and oncogenic mechanisms driving adult T-ALL, we analyzed a series of 57 T-ALL samples treated in the Eastern Cooperative Oncology Group (ECOG) E2993 protocol ([@bib22]) using gene expression oligonucleotide microarrays. Unsupervised analysis and consensus clustering of microarray gene expression data revealed the presence of 2 stable gene expression clusters (Cluster I and II) encompassing approximately half of the tumor samples analyzed each ([Fig. 1 A](#fig1){ref-type="fig"}). Supervised analysis demonstrated that each of these two groups is characterized by a distinct gene expression program encompassing 365 differentially expressed unique genes (fold change \>1.5; P \< 0.0001; [Fig. 1 B](#fig1){ref-type="fig"}). Similar results were obtained in an independent validation set of 30 adult T-ALLs ([@bib7]). Thus, consensus clustering identified two robust clusters encompassing 12 and 18 samples, respectively in this series (Fig. S1). Moreover, cross analysis of clusters identified in the discovery and validation datasets using gene set enrichment analysis (GSEA) demonstrated a high level of enrichment in the expression signatures associated with clusters I and II in our discovery series in the clusters identified in this second dataset and vice versa, a high level of enrichment of a high level of enrichment in differentially expressed genes between clusters I and II in our validation series in the clusters identified in this our original dataset ([Fig. S1](http://www.jem.org/cgi/content/full/jem.20112239/DC1){#supp1}).

![**Gene expression profiling identifies high prevalence of early immature leukemias in adult T-ALL.** (A) Consensus clustering of microarray gene expression data of 57 adult T-ALL samples. (B) Top 50 differentially expressed genes between adult T-ALL cluster I and cluster II samples. Genes in the heat map are shown in rows and each individual sample is shown in one column. The scale bar shows color-coded differential expression from the mean in standard deviation units with red indicating higher levels and blue lower levels of expression. (C) GSEA analysis of early immature/*LYL1*-positive, early cortical/*TLX1*-positive, and late cortical/*TAL1*-positive associated genes in the gene expression clusters I and II identified in adult T-ALL. (D) GSEA of genes associated with pediatric ETP-T-ALLs in adult T-ALL gene expression clusters.](JEM_20112239_Fig1){#fig1}

Gene expression profiling of pediatric T-ALLs has defined distinct molecular subgroups associated with the activation of specific transcription factor oncogenes and unique gene expression signatures reflecting a distinct arrest during T cell development ([@bib15], [@bib16]; [@bib28]; [@bib20]). Early immature/*LYL1*-positive T-ALLs show an early block at the double-negative stage of thymocyte development ([@bib15]). In contrast, early cortical T-ALLs are characteristically CD1a, CD4, and CD8 positive and are frequently associated with translocations inducing aberrant expression of the *TLX1* and *TLX3* homeobox transcription factor oncogenes ([@bib15]). Finally, late cortical thymocyte T-ALLs show expression of CD4, CD8, and CD3 and activation of the *TAL1* transcription factor oncogene ([@bib15]; [@bib28]; [@bib20]). GSEA of genes associated with these pediatric molecular groups of T-ALL ([@bib15]) against the two clusters of adult T-ALLs identified in our series showed a highly significant enrichment of *LYL1*/immature T-ALL--associated genes in cluster I, whereas cluster II was associated with *TLX1*/early cortical and *TAL1*/late cortical T-ALL signatures ([Fig. 1 C](#fig1){ref-type="fig"}). Consistently, all *TLX1* (*n* = 5) and *TLX3* (*n* = 5), and 8/10 *TAL1* high/*LMO1*/*LMO2*, expression leukemias in this series were included in cluster II.

Notably, transcriptionally defined early immature adult T-ALLs in cluster I showed an early arrest in T cell development and were characterized by the expression of cytoplasmic CD3 together with early hematopoietic markers such as CD34 (22/29, 76%) and CD133 (14/29, 48%) and myeloid-associated antigens such as CD13 (19/29, 65%), CD33 (16/29, 55%), and CD11b (16/29, 55%; [Table S1](http://www.jem.org/cgi/content/full/jem.20112239/DC1){#supp2}). However, despite these common features, we could still identify three different immunophenotype categories within this group based on the expression of CD5. Thus, 10/29 cases (34%) showed complete absence of surface CD5 expression, 16/29 (55%) showed low levels of surface CD5 expression, and 3/29 (11%) were strongly CD5 positive (Table S1). Importantly, weak expression of CD5 in immature pediatric T-ALL leukemias has recently been associated with a gene expression program resembling early T cell progenitors and defines a group of childhood T-ALLs with poor prognosis ([@bib9]). To test the relationship of adult T-ALLs with early T cell precursor (ETP) pediatric T-ALLs, we performed GSEA of adult T-ALL clusters I and II using a gene set of ETP-T-ALL--associated transcripts ([@bib9]). This analysis showed a high level of enrichment of transcripts associated with this poor prognostic pediatric T-ALL group in adult immature/cluster I T-ALLs ([Fig. 1 D](#fig1){ref-type="fig"}).

To explore the relationship between the genetic program associated with adult early immature T-ALLs and normal thymocytes, we performed GSEA analysis of gene expression signatures associated with distinct human thymocyte subsets including early double-negative (CD34^+^, CD1a^−^, CD4^−^, CD8^−^), late double-negative (CD34^+^, CD1a^+^, CD4^−^, CD8^−^), immature single-positive (CD4^+^, CD8^−^, CD3^−^), early double-positive (CD4^+^, CD8^+^, CD3^−^), late double-positive (CD4^+^, CD8^+^, CD3^+^), mature CD4 single-positive (CD4^+^, CD8^−^, CD3^+^), and mature CD8 single-positive (CD4^−^, CD8^+^, CD3^+^) cells. This analysis demonstrated a significant enrichment of genes characteristic for the earliest double-negative (CD34^+^, CD1a^−^, CD4^−^, CD8^−^) T cell progenitors in the early immature T-ALL group ([Fig. 2 A](#fig2){ref-type="fig"}). Notably, early double-negative thymocytes are not yet committed to T cell development and retain multilineage potential ([@bib5]). Therefore, we used a similar approach to analyze the relationship of early immature T-ALLs with other hematopoietic lineages and progenitor populations ([@bib24]). Surprisingly, this analysis revealed a significant enrichment of genes up-regulated in long-term hematopoietic stem cells ([Fig. 2 B](#fig2){ref-type="fig"}) and in granulocyte-monocyte progenitors ([Fig. 2 C](#fig2){ref-type="fig"}) in this group. These results, together with the high prevalence of expression of immature (CD34, CD133) and myeloid (CD13, CD33, and CD11b) surface markers in these leukemias (Table S1) made us consider the possibility that early immature adult T-ALL tumors may be transcriptionally and genetically related to acute myeloid leukemias (AMLs).

![**Myeloid and stem cell features of immature adult T-ALL.** (A--C) GSEA of transcripts significantly up-regulated in early immature adult T-ALL in gene expression signatures obtained from human early double negative thymocytes (CD34^+^CD1a^−^CD4^−^CD8^−^; A) against all other thymocyte groups, long term hematopoietic stem cells (LT-HSC; B), and granulocyte-monocyte progenitors (GMP; C) against all other hematopoietic populations. (D and E) GSEA of AML- (D) or ALL-associated (E) transcripts in early immature (cluster I) versus other (cluster II) adult T-ALLs. (F) Differential distribution of myeloid-specific lesions in immature (cluster I) versus other (cluster II) adult T-ALLs.](JEM_20112239_Fig2){#fig2}

To test this hypothesis, we analyzed the enrichment of lymphoid and myeloid leukemia gene expression signatures ([@bib17]) in immature adult T-ALLs. This analysis revealed a highly significant enrichment of AML-associated transcripts in the early immature T-ALL cluster I group, whereas ALL associated transcripts were enriched in the T-ALL cluster II samples ([Fig. 2, D and E](#fig2){ref-type="fig"}). Based on this observation, we hypothesized that myeloid-specific genetic alterations might be uniquely present in immature adult T-ALLs. Strikingly, mutation analysis of AML oncogenes and tumor suppressor genes revealed the presence of myeloid mutations targeting *IDH1*, *IDH2*, *DNMT3A*, *FLT3*, and *NRAS* in 14/29 (48%) of immature adult T-ALL cases, whereas only 1/28 (3.5%) of all other adult T-ALLs showed a mutation in *NRAS* (P = 0.0001; [Fig. 2 F](#fig2){ref-type="fig"} and [Table S2](http://www.jem.org/cgi/content/full/jem.20112239/DC1){#supp3}). In addition, immature adult T-ALL samples showed a lower prevalence of prototypical T-ALL genetic alterations such as activating mutations in the *IL7R* gene (1/29 \[3.5%\] immature adult T-ALLs vs. 6/28 \[21.5%\] of all other adult T-ALL samples; P \< 0.05) and mutations in *NOTCH1* and *FBXW7* activating the NOTCH-signaling pathway (12/29 \[41%\] immature adult T-ALLs vs. 26/28 \[93%\] of all other adult T-ALLs; P \< 0.05; Table S2). Notably, myeloid-specific gene alterations and mutations activating IL7R or NOTCH signaling were overlapping in 7/29 (24%) of all immature adult T-ALLs (Table S2). Overall, these results show that early immature adult T-ALLs are a gray zone leukemia category characterized by the presence of overlapping myeloid and T-lymphoid immunophenotypic features and genetic alterations.

Notably, a similar cooccurrence of both T lymphoid and myeloid characteristics has been previously documented in rare leukemias harboring the translocation t(8;12)(q13;p13), which results in the fusion of the *ETV6* tumor suppressor and the *NCOA2* gene ([@bib29]; [@bib20]). Given the prominent role of *ETV6* in hematopoietic stem cell homeostasis ([@bib19]) and to test a possible broader role of *ETV6* in the pathogenesis of T-ALL, we screened all coding exons of *ETV6* for the presence of somatic mutations in an extended series of adult leukemia cases. This analysis revealed the presence of *ETV6* mutations in 10 out of 82 (12%) adult T-ALL samples analyzed ([Fig. 3, A--C](#fig3){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). Strikingly, *ETV6* mutations were exclusively found in early immature adult T-ALLs with expression of the early hematopoietic marker CD34, cytoplasmic CD3, and the myeloid-associated antigen CD33 in the absence of CD4 and CD8 ([Table S3](http://www.jem.org/cgi/content/full/jem.20112239/DC1){#supp4}). The overall incidence of *ETV6* mutations in immature adult T-ALL in this series was 10 out of 41 (24%). In seven cases, *ETV6* mutations corresponded to frameshift insertions or deletions in the N-terminal part of the protein, whereas the three remaining alleles corresponded to C-terminal truncating alleles (2 frameshift insertions and deletions and an exon 8 splice acceptor site mutation; [Fig. 3 A](#fig3){ref-type="fig"}). Analysis of bone marrow remission genomic DNA confirmed the somatic origin of *ETV6* mutations (three frameshift and one splice site) in each of the four patient samples with available material ([Fig. 3, B and C](#fig3){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). *ETV6* mutations found in T-ALL were heterozygous in 8 out of 10 cases (80%) with two patient samples showing copy neutral loss of heterozygosity resulting in homozygous N-terminal and C-terminal truncating alleles ([Table 1](#tbl1){ref-type="table"}). RT-PCR analysis confirmed expression of the remaining wild-type *ETV6* allele in heterozygous *ETV6* mutant adult T-ALL samples ([Fig. 3 D](#fig3){ref-type="fig"}). In addition, and in contrast with the lower incidence of *NOTCH1* mutations present in the immature group, 8/10 (80%) of *ETV6* mutant T-ALL cases showed mutations in *NOTCH1* ([Table 1](#tbl1){ref-type="table"}), suggesting a specific interaction between the oncogenic programs activated by *NOTCH1* and mutational loss of *ETV6* in the pathogenesis of adult immature T cell lymphoblastic leukemia.

![***ETV6* mutations in early immature adult T-ALL.** (A) Schematic representation of the structure of the ETV6 protein. The N-terminal pointed (PNT) homodimerization domain and the C-terminal DNA-binding domain (ETS-domain) are indicated. *ETV6* mutations identified in primary adult T-ALL samples are shown. Filled circles represent frameshift mutations, whereas the splice acceptor mutation in the exon 8 splice acceptor sequence is depicted as an open circle. (B and C) Representative DNA sequencing chromatograms of paired diagnosis and remission genomic T-ALL DNA samples showing a somatic frameshift mutation in exon 6 (B) and a splice acceptor mutation in exon 8 of *ETV6* (C). (D) Sequence analysis of paired *ETV6* genomic DNA and cDNA shows biallelic expression of wild-type and mutant ETV6 transcripts.](JEM_20112239_Fig3){#fig3}

###### 

*ETV6* mutations in early immature adult T-ALL

           *ETV6* mutations   T-ALL specific lesions Myeloid specific lesions                                                
  ---- --- ------------------ ------------------------------------------------- --------- --------- ---- --------- --------- ---------
  3    3   S105fs             het                                               NA        **MUT**   WT   **MUT**   WT        WT
  5    8   R417fs             het                                               somatic   **MUT**   WT   WT        WT        WT
  18   3   Y103fs             homo (LOH)                                        somatic   **MUT**   WT   WT        WT        WT
  24   4   S130fs             het                                               somatic   **MUT**   WT   WT        WT        WT
  27   2   P50fs              het                                               NA        **MUT**   WT   **MUT**   WT        WT
  58   5   L178fs             het                                               NA        WT        WT   WT        **MUT**   **MUT**
  59   5   V158fs             het                                               NA        **MUT**   WT   WT        WT        **MUT**
  60   3   V66fs              het                                               NA        WT        WT   WT        WT        WT
  61   6   V345fs             het                                               somatic   **MUT**   WT   WT        WT        WT
  62   6   N356fs             homo (LOH)                                        NA        **MUT**   WT   WT        WT        WT

LOH, loss of heterozygosity; NA, not available

The *ETV6* tumor suppressor gene is frequently translocated in lymphoid and myeloid hematopoietic tumors and encodes a transcriptional repressor with an N-terminal pointed (PNT) homodimerization domain and a C-terminal ETS DNA-binding domain ([@bib6]). Transfection of plasmids driving the expression of N-terminal truncating *ETV6* mutations (Y103fs, S105fs) found in adult T-ALL resulted in the activation of the M208 and M240 internal translation initiation sites ([@bib3]) and the expression of N-terminal truncated protein products (23 and 28 kD) devoid of the PNT domain and retaining the DNA-binding domain ([Fig. 4 A](#fig4){ref-type="fig"}). C-terminal *ETV6* truncating mutations (V345fs, N356fs) resulted in the expression of C-terminal truncated polypeptides (42 and 44 kD, respectively; [Fig. 4 B](#fig4){ref-type="fig"}). Consistently, Western blot analysis of a primary patient sample harboring a homozygous N-terminal truncating mutation detected the presence of shorter mutant ETV6 isoforms (23 and 28 kD; [Fig. 4 C](#fig4){ref-type="fig"}), whereas analysis of a sample with a heterozygous C-terminal mutation revealed the expression of both wild-type (50 and 57 kD) and truncated (42 kD) ETV6 proteins ([Fig. 4 C](#fig4){ref-type="fig"}).

![**Functional analysis of truncating *ETV6* mutant alleles.** (A and B) Western blot analysis of FLAG-tagged N-terminal (Y103fs, S105fs) (A) and C-terminal (V345fs, N356fs) (B) *ETV6* mutants expressed in HEK293T cells. The FLAG epitope was introduced in the C terminus of the N-terminal Y103fs and S105fs mutants and in the N terminus of the C-terminal ETV6 V345fs and N356fs mutants. Blots were probed with anti-FLAG or anti-GAPDH as loading control. (C) Lysates from primary adult T-ALL samples harboring a heterozygous C-terminal (V345fs, \#61) and a homozygous N-terminal (Y103fs,\#18) *ETV6* mutation were analyzed by Western blot. Wild-type ETV6 proteins are detected as 50 and 57 kD anti-ETV6 immunoreactive bands and anti-GAPDH as loading control. (D) Effects of *ETV6* mutant alleles in the activity an ETV6-responsive reporter plasmid (pGL2-754TR). Luciferase activity is shown relative to empty vector and normalized using an internal control plasmid expressing Renilla luciferase. Experiments were performed in triplicate and repeated at least twice. (E) Luciferase assay analyzing the effects of increasing amounts (indicated by wedges) of C-terminal (V345fs) and N-terminal (S105fs) *ETV6* mutants on the activity of wild-type ETV6. Experiments were performed in triplicate and repeated at least twice. (F) Supervised analysis of *ETV6* mutant versus *ETV6* wild-type gene expression signatures in early immature adult T-ALLs (P \< 0.001). Top 50 differentially expressed genes are shown. Genes in the heat map are shown in rows, each individual sample is shown in one column. The scale bar shows color-coded differential expression from the mean in standard deviation units, with red indicating higher levels and blue lower levels of expression.](JEM_20112239_Fig4){#fig4}

To elucidate the functional consequences of *ETV6* alterations, we performed luciferase reporter assays using an ETV6-responsive reporter construct (pGL2-754TR) derived from the stromelysin-1 gene ([@bib13]). In line with the role of ETV6 as transcriptional repressor, expression of wild-type ETV6 strongly decreased luciferase activity ([Fig. 4 D](#fig4){ref-type="fig"}). In contrast, C-terminal (V345fs; N356fs) and N-terminal (Y103fs; S105fs) ETV6 mutants were functionally inactive with no transcriptional repression activity ([Fig. 4 D](#fig4){ref-type="fig"}). Moreover, expression of C-terminal (V345fs) and N-terminal (S105fs) *ETV6* mutants abolished the transrepression effects of wild-type *ETV6* ([Fig. 4 E](#fig4){ref-type="fig"}), suggesting that these mutant *ETV6* alleles harbor dominant-negative activity. Consistently, supervised analysis of microarray gene expression signatures of *ETV6* wild-type (*n* = 19) and *ETV6*-mutated (*n* = 9) immature adult T cell leukemias showed that *ETV6*-mutated cases have a characteristic gene expression signature dominated by up-regulated transcripts ([Fig. 4 F](#fig4){ref-type="fig"} and [Fig. S2](http://www.jem.org/cgi/content/full/jem.20112239/DC1){#supp5}), which included the myeloid marker *CD33* and genes involved in leukemia development and stem cell homeostasis, such as *HOXA13* ([@bib30]; [@bib2]), *TP63* ([@bib4]; [@bib10]), *PTEN* ([@bib35]; [@bib37]), and *PRDM16* ([@bib11]; [@bib8]), which is a gene translocated to the *ETV6* locus in AML ([@bib12]; [Fig. 4 F](#fig4){ref-type="fig"}). Notably, all *ETV6* mutant T-ALL samples in our series were characteristically CD33 positive (5/5 \[100%\] immature *ETV6* mutant T-ALLs vs. 11/24 \[46%\] immature *ETV6* wild-type T-ALLs; P \< 0.05; Table S3).

After these results, and to test the transcriptional effects of *ETV6* inactivation in immature T-ALL, we analyzed the gene expression changes induced upon small interfering RNA (siRNA)-mediated knockdown of *ETV6* in LOUCY cells, a T-ALL cell line with a transcriptional program highly related to that of immature T-ALLs ([Fig. 5 A](#fig5){ref-type="fig"}, [Fig. S3](http://www.jem.org/cgi/content/full/jem.20112239/DC1){#supp6}). Notably, GSEA analysis of this *ETV6* knockdown signature showed a significant enrichment in genes that are characteristically up-regulated in *ETV6* mutant immature T-ALLs, including *HOXA13*, *PRDM16*, *PTEN*, and *CD33* (P = 0.016; [Fig. 5 B](#fig5){ref-type="fig"}).

![**Transcriptional program regulated by ETV6 in T-ALL.** (A) RT-PCR (top) and Western blot (bottom) analysis of *ETV6* expression in LOUCY cells expressing control siRNA or one of two ETV6-specific siRNAs. (B) GSEA of the early immature *ETV6* mutant T-ALL--associated transcripts in control siRNA versus *ETV6* knockdown LOUCY cells. Heatmap of genes up-regulated in early immature *ETV6* mutant T-ALL most differentially expressed in control siRNA versus *ETV6* knockdown LOUCY cells. The myeloid marker *CD33* and genes involved in leukemia development and stem cell homeostasis are shown in red. Genes in the heat map are shown in rows and each individual sample is shown in one column. The scale bar shows color-coded differential expression from the mean in standard deviation units, with red indicating higher levels and blue lower levels of expression.](JEM_20112239_Fig5){#fig5}

Overall, our results demonstrate a high prevalence of early immature T-ALLs in adult T-ALL, which show increased heterogeneity in their immunophenotypes compared with pediatric ETP-TALLs, mixed lymphoid and myeloid characteristics, and frequent truncating mutations in the *ETV6* tumor suppressor gene.

MATERIALS AND METHODS
=====================

### Patient samples and cell lines.

Leukemic DNA and cryopreserved lymphoblast samples were provided by the Eastern Cooperative Oncology Group (ECOG). All samples were collected in clinical trials E2993 ([@bib22]) and C10403. Informed consent to use leftover material for research purposes was obtained from all the patients at trial entry according to the Declaration of Helsinki. T cell phenotype was confirmed by flow cytometry. In total, 82 adult T-ALL samples were used in this study, including 57 samples used for the gene expression profiling study and mutation analysis and 25 additional cases used for mutation screening.

The LOUCY cell line was cultured in RPMI-1640 media supplemented with 10% fetal bovine serum, 100 U/ml penicillin G, and 100 µg/ml streptomycin at 37°C in a humidified atmosphere under 5% CO~2~. HEK293T cells were cultured under similar conditions in DME media.

### Sorting of human thymocyte populations from human thymus.

Thymus samples were obtained as surgical tissue discards from 3 pediatric patients (age from 7 d to 6 mo) undergoing cardiac surgery at the New York Presbyterian Hospital. Single-cell suspensions were prepared by dissecting the thymus into small pieces and passing the tissue through a cell strainer (diameter 70 μm), and mononuclear cells were isolated by Ficoll density centrifugation (GE Healthcare). CD34^+^ human thymocyte populations were obtained by positive selection using magnetically activated cell sorting using the CD34 MicroBead kit (Miltenyi Biotec) and by negative selection using the CD3 MicroBead kit (Miltenyi Biotec). Magnetically isolated CD34^+^ cells were then labeled with fluorophore-conjugated monoclonal antibodies against CD34 (CD34-APC) and CD1a (CD1-PE; BD). Early double negative thymocytes (CD34^+^CD1a^−^CD3^−^CD4^−^CD8^−^) and late double negative thymocytes (CD34^+^CD1a^+^CD3^−^CD4^−^CD8^−^) were isolated by FACS. Immature single-positive thymocytes (CD4^+^CD8^−^CD3^−^), were isolated by FACS after immunomagnetic depletion of total thymocytes with the CD3 MicroBead kit (Miltenyi Biotec) and immunostaining with CD4-PE (BD) and CD34-FITC antibodies. Early double-positive cells (CD4^+^CD8^+^CD3^−^) were isolated by FACS from CD3 immunodepleted cells after staining with CD4-PE and CD8-FITC (BD) antibodies. Late double-positive (CD4^+^CD8^+^CD3^+^) and mature single-positive CD4 (CD4^+^CD3^+^) and CD8 (CD8^+^CD3^+^) thymocytes were FACS after triple immunolabeling with CD4-PE, CD8-FITC, and CD3-APC (BD) antibodies. Cell sorting was performed with a FACSDiva cell sorter (BD), and the purity of all sorted populations was \>95%.

### Microarray gene expression profiling of normal T cell subsets and primary adult T-ALL samples.

RNA isolation from sorted subsets of human thymocytes was performed in triplicate using the RNeasy Micro kit (QIAGEN) according to manufacturer's protocol. Next, 10 ng of RNA from each T cell subset was amplified using the Ovation PicoSL WTA System (NuGen), labeled by the Encore BiotinIL Module (NuGen), and hybridized to the HumanHT-12 v4 Expression BeadChip (Illumina) according to manufacturer's protocol. Similarly, RNA isolation from lymphoblast obtained from adult T-ALL patient samples was achieved using the RNeasy plus mini kit (QIAGEN) according to manufacturer's protocol. Next, 500 ng of RNA was amplified and biotinylated using the TotalPrep RNA Amplification kit (Invitrogen) and hybridized to the HumanHT-12 v4 Expression BeadChip (Illumina).

Gene expression profiling data from 57 adult T-ALL patients and normal T cell subsets were normalized using quantile normalization without background subtraction. Unsupervised consensus clustering was performed with K = 2, as previously described ([@bib23]), using the GenePattern application ([@bib18]). Genes differentially expressed between cluster I and cluster II adult T-ALL cases were identified using the Comparative Marker Selection application in GenePattern ([@bib18]) using a nonparametric P value calculation with 1,000 permutations.

A validation series of 30 previously reported adult T-ALL microarray data ([@bib7]) was normalized with GC-RMA using the open-source Bioconductor project ([www.bioconductor.org](http://www.bioconductor.org){#supp7}) within the statistical programming language R (<http://cran.r-project.org/>). In this series, we selected the top 250 most variable probes from the unsupervised consensus clustering analysis of the 57 ECOG T-ALL expression samples in our discovery series matched by gene names for consensus clustering as described in the previous paragraph. The relationship of clusters identified in the discovery series and validation series was established by cross GSEA analysis ([@bib31]) of the top up- and down-regulated genes (Student's *t* test, P \< 0.0001) in clusters I and cluster II of one series against the list of genes ranked by the t-score (cluster I vs. cluster II) in the other.

Enrichment of early immature/*LYL1*-positive, early cortical/*TLX1*, and late cortical/*TAL1*-associated genes in the gene expression clusters identified in our adult T-ALL series was analyzed by GSEA using the *t* test metric and 1,000 permutations of the genes. In addition, enrichment of myeloid- and lymphoid-associated genes was studied by a similar GSEA analysis using myeloid and lymphoid ([@bib17]) gene sets. Similarly, we analyzed the relationship of the early immature adult T-ALL signature with that of different sorted human hematopoietic populations ([@bib24]; Gene Expression Omnibus \[GEO\] accession no. GSE24759\], the gene expression profiles generated for the specific populations of sorted human thymocytes, and gene sets associated with ETP T-ALL ([@bib9]), as described above. GEO accession nos. for adult T-ALL and normal thymocyte microarray data analyzed here are GSE33469 and GSE33470, respectively.

Microarray data from human T-ALL cell lines ([@bib26]; GEO accession no. GSE5682) were analyzed for their relationship with cluster I (early immature) and cluster II T-ALL signatures by GSEA using the Student's *t* test metric and 1,000 permutations of the genes.

### Sequence analysis.

All exon sequences from *ETV6* were amplified from genomic DNA by PCR and analyzed by direct dideoxynucleotide sequencing. Mutational hotspot regions for *FLT3*, *DNMT3A*, *IDH1*, *IDH2*, *NOTCH1*, *IL7R*, and *FBXW7* were sequenced. Primer sequences used for *FLT3* ([@bib33]), *DNMT3A* ([@bib21]), *IDH1* ([@bib1]), *IDH2* ([@bib1]), *NOTCH1* ([@bib34]), *IL7R* ([@bib36]), and *FBXW7* ([@bib32]) have been previously described. Primer sequences used for *ETV6* sequencing are shown in [Table S4](http://www.jem.org/cgi/content/full/jem.20112239/DC1){#supp8}.

### Luciferase reporter assays.

We generated N-terminal or C-terminal FLAG-tagged wild-type and mutant *ETV6* constructs in the pCDNA3.1 (-) plasmid by direct PCR cloning from cDNA obtained from primary *ETV6* wild-type and mutant adult T-ALL samples. A FLAG epitope was introduced into the N terminus of the C-terminal ETV6 V345fs and N356fs mutants and in the C terminus of the N-terminal Y103fs and S105fs mutants. We tested the *ETV6* transcriptional repression activity in a luciferase reporter assay using the pGL2-T574 reporter construct ([@bib13]). In these assays, we transfected HEK293T cells with 50 ng of wild-type pcDNA3-ETV6 or different types of N-terminal and C-terminal ETV6 mutants, together with a plasmid driving the expression of the Renilla luciferase gene (pCMV-Renilla) used as transfection control. Alternatively, we transfected HEK293T cells with a constant amount of wild-type pcDNA3-ETV6 in combination with increased concentrations of N-terminal and C-terminal ETV6 mutant constructs at 1:1, 1:2, and 1:3 ratios. We measured luciferase activity 48 h after transfection with the Dual-Luciferase Reporter assay kit (Promega).

### Western blot.

Western blot analysis was performed using a mouse monoclonal antibody against ETV6 (1:5,000; Abnova), a rabbit antibody against FLAG epitope (1:1,000; Cell Signaling Technology), and a mouse monoclonal antibody GAPDH (1:1,000; Santa Cruz Biotechnology, inc.) using standard procedures.

### *ETV6* siRNA knockdown.

For siRNA-mediated knockdown of *ETV6* in the LOUCY T-ALL cell line, we performed electroporation of 50 nM *ETV6*-specific siRNAs (Applied Biosystems) or 50 nM of scramble siRNAs as control, using an exponential decay pulse (300 V, 1000 µF; Genepulser MxCell, Bio-Rad). After 72 h, RNA was isolated using the RNeasy plus mini kit (QIAGEN) according to manufacturer's protocol. Knockdown of *ETV6* was evaluated by RT-PCR and Western blot analysis, after which the siRNA showing the highest *ETV6* knockdown (siRNA ETV6\#1) was selected for further analysis. Finally, gene expression profiling of biological replicates for LOUCY siRNA scramble control and LOUCY siRNA ETV6\#1 was performed using the HumanHT-12 v4 Expression BeadChip as described previously for the primary leukemia samples.

The GEO accession code for the microarray data of LOUCY cells upon siRNA ETV6 knockdown analyzed here is GSE33820.

### Statistical analysis.

The Fisher's exact test was used to compare the frequency of specific genomic lesions between of immature and other adult T-ALL patients.

### Online supplemental material.

Fig. S1 shows a consensus clustering analysis of a validation series of 30 adult T-ALLs and cross GSEA analysis between clusters identified in the discovery and validation cohorts. Fig. S2 shows a heatmap of the supervised analysis from *ETV6* mutant versus *ETV6* wild-type gene expression signatures in early immature adult T-ALLs (P \< 0.001; FC \> 1.25). Fig. S3 shows GSEA analysis of transcripts significantly up-regulated in early immature adult T-ALL in gene expression signatures obtained from a panel of T-ALL cell lines. Table S1 shows an overview of the immunophenotypic features of the adult T-ALL samples included in this study (*n* = 57). Table S2 shows an overview of the myeloid and T-lymphoid specific genetic alterations in adult T-AL. Table S3 shows the immunophenotypic features of the *ETV6* mutant adult T-ALL samples (*n* = 10). Table S4 shows the primer sequences used for *ETV6* mutations analysis. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20112239/DC1>.
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